Aditxt Inc. (ADTX) said that it has launched high-sensitivity neutralizing antibody test to detect individual immune response to COVID-19.
In Monday pre-market trading, ADTX was trading at $2.68 up $0.18 or 7.20%.
The company noted that AditxtScore for COVID-19, which was first introduced in August of 2020, differentiates itself from traditional antibody tests by delivering a detailed view of an individual's immune response to multiple antigens associated with the SARS-CoV-2 virus.
"Everyone's immune response is unique to that individual. We have been studying individual immune responses to COVID-19 and COVID-19 vaccination," said Amro Albanna, Co-founder and Chief Executive Officer of Aditxt.
AditxtScore for COVID-19 now includes virus-sSpecific infection blocking antibodies that assess the strength of an individual's immune response to SARS-CoV-2.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.